risedronic acid has been researched along with clodronic acid in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (23.81) | 18.2507 |
2000's | 11 (52.38) | 29.6817 |
2010's | 3 (14.29) | 24.3611 |
2020's | 2 (9.52) | 2.80 |
Authors | Studies |
---|---|
Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
Licata, AA | 1 |
Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
Mundy, GR | 1 |
Halasy-Nagy, JM; Masarachia, PJ; Reszka, AA; Rodan, GA | 1 |
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
Watts, NB | 1 |
Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R | 1 |
Hershman, D; Narayanan, R | 1 |
Abrahamsen, B; Brixen, KT; Kassem, MS; Mosekilde, L | 1 |
Kikuchi, T; Shinoda, H; Sodek, J; Suzuki, K; Takeyama, S; Yamada, S | 1 |
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
Aerts, K; Bridts, CH; Cos, P; De Clerck, LS; De Tollenaere, CB; Dombrecht, EJ; Ebo, DG; Schuerwegh, AJ; Stevens, WJ; Van Offel, JF | 1 |
Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R | 1 |
Mészaros, Á; Veszelyné Kotán, E | 2 |
Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
12 review(s) available for risedronic acid and clodronic acid
Article | Year |
---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Bisphosphonates as cancer drugs.
Topics: Antineoplastic Agents; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasm Proteins; Neoplasms; Osteolysis; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Risedronic Acid; Transforming Growth Factor beta | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
[Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Radionuclide Imaging; Risedronic Acid | 2005 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome | 2013 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
9 other study(ies) available for risedronic acid and clodronic acid
Article | Year |
---|---|
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Topics: Alendronate; Animals; Apoptosis; Calcium Channel Blockers; Caspase Inhibitors; Caspases; Clodronic Acid; Diphosphonates; Diterpenes; Enzyme Activation; Etidronic Acid; Macrophage Colony-Stimulating Factor; Male; MAP Kinase Kinase Kinases; Mevalonic Acid; Mice; Mice, Inbred BALB C; Osteoclasts; Protein Prenylation; Protein Serine-Threonine Kinases; Risedronic Acid; Signal Transduction; Staurosporine; Time Factors | 1999 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Tolerance; Etidronic Acid; Female; Humans; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Pain; Pamidronate; Parathyroid Hormone; Risedronic Acid; Treatment Outcome | 2004 |
Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.
Topics: Acid Phosphatase; Actins; Alkaline Phosphatase; Animals; Animals, Newborn; Bone Density; Bone Resorption; Clodronic Acid; Collagen Type I; Diphosphonates; Etidronic Acid; Fluorescent Dyes; Integrin beta3; Integrin-Binding Sialoprotein; Isoenzymes; Lipopolysaccharides; Mice; Organ Culture Techniques; Osteoclasts; Osteopontin; Parathyroid Hormone; Risedronic Acid; Sialoglycoproteins; Skull; Tartrate-Resistant Acid Phosphatase | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation.
Topics: Animals; Antioxidants; Boron Compounds; Cattle; Cells, Cultured; Chondrocytes; Clodronic Acid; Diphosphonates; Edetic Acid; Etidronic Acid; Ferrous Compounds; Flow Cytometry; Hydrogen Peroxide; Lipid Peroxidation; Pamidronate; Risedronic Acid; Simvastatin; tert-Butylhydroperoxide | 2006 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |